| scholarly article | Q13442814 |
| P2093 | author name string | K Yamamoto | |
| K Takahashi | |||
| N Kojima | |||
| T Takahashi | |||
| K Kitano | |||
| S Uchida | |||
| M Arai | |||
| H Toyoda | |||
| H Tomoike | |||
| N Fukuhara | |||
| A Kozakai | |||
| E Gunji | |||
| J Asami | |||
| L Okumura-Kitajima | |||
| P2860 | cites work | Efficient selection for high-expression transfectants with a novel eukaryotic vector | Q27860810 |
| Renal Na(+)-glucose cotransporters | Q28141135 | ||
| Molecular Analysis of the SGLT2 Gene in Patients with Renal Glucosuria | Q28211392 | ||
| Molecular basis for glucose-galactose malabsorption | Q28215903 | ||
| Structure, function, and regulation of the mammalian facilitative glucose transporter gene family | Q28292160 | ||
| Molecular characteristics of Na(+)-coupled glucose transporters in adult and embryonic rat kidney | Q28580452 | ||
| The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose | Q34121476 | ||
| Human cardiomyocytes express high level of Na+/glucose cotransporter 1 (SGLT1) | Q34264473 | ||
| SGLT2 mediates glucose reabsorption in the early proximal tubule. | Q34457264 | ||
| Oral antihyperglycemic therapy for type 2 diabetes: scientific review | Q34492673 | ||
| Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level | Q34575066 | ||
| Molecular physiology of sodium-glucose cotransporters | Q34724942 | ||
| Phlorizin: a review | Q35995949 | ||
| Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats | Q39999985 | ||
| Insulin regulation of the two glucose transporters in 3T3-L1 adipocytes | Q42831625 | ||
| (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment | Q43123822 | ||
| Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models | Q46516165 | ||
| Guide to Receptors and Channels (GRAC), 4th Edition | Q56639335 | ||
| T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes | Q78238839 | ||
| Studies on the diabetogenic action of streptozotocin (NSC-37917) | Q94295200 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hyperglycemia | Q271993 |
| P304 | page(s) | 181-191 | |
| P577 | publication date | 2011-09-01 | |
| P1433 | published in | British Journal of Pharmacology | Q919631 |
| P1476 | title | TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity | |
| P478 | volume | 164 |
| Q50266611 | A simple and rapid LC-MS/MS method for quantitation of luseogliflozin in rat plasma and its application to a PK study |
| Q35666237 | Absence of Drug-Drug Interactions Between Luseogliflozin, a Sodium-Glucose Co-transporter-2 Inhibitor, and Various Oral Antidiabetic Drugs in Healthy Japanese Males |
| Q90400823 | Comparative Pharmacokinetics and Pharmacodynamics of a Novel Sodium-Glucose Cotransporter 2 Inhibitor, DWP16001, with Dapagliflozin and Ipragliflozin |
| Q64274919 | Diuretic Effects of Sodium Glucose Cotransporter 2 Inhibitors and Their Influence on the Renin-Angiotensin System |
| Q90245294 | Effect of dapagliflozin alone and in combination with insulin in a rat model of type 1 diabetes |
| Q88538234 | Effect of the sodium-glucose cotransporter 2 inhibitor luseogliflozin on pancreatic beta cell mass in db/db mice of different ages |
| Q36852567 | Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats |
| Q41154151 | Effects of luseogliflozin, a sodium-glucose co-transporter 2 inhibitor, on 24-h glucose variability assessed by continuous glucose monitoring in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, crossov |
| Q38130748 | Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes. |
| Q44418300 | Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus |
| Q51692185 | In vitro evaluation of potential drug interactions mediated by cytochrome P450 and transporters for luseogliflozin, an SGLT2 inhibitor. |
| Q38075117 | Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus |
| Q38264051 | Luseogliflozin for the treatment of type 2 diabetes |
| Q50509031 | Luseogliflozin, an SGLT2 Inhibitor, in Japanese Patients With Mild/Moderate Hepatic Impairment: A Pharmacokinetic Study. |
| Q57485821 | Luseogliflozin: First Global Approval |
| Q51679305 | Metabolite profiling and enzyme reaction phenotyping of luseogliflozin, a sodium-glucose cotransporter 2 inhibitor, in humans. |
| Q64976338 | Pharmacokinetics and Pharmacodynamics of Luseogliflozin, a Selective SGLT2 Inhibitor, in Japanese Patients With Type 2 Diabetes With Mild to Severe Renal Impairment. |
| Q35558413 | Pharmacokinetics, Pharmacodynamics, and Safety of Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Single-blind, Placebo-controlled Trial. |
| Q46650678 | Preclinical metabolism and disposition of luseogliflozin, a novel antihyperglycemic agent |
| Q36131466 | Randomized, Controlled, Thorough QT/QTc Study Shows Absence of QT Prolongation with Luseogliflozin in Healthy Japanese Subjects |
| Q36004330 | Renoprotective effects of combined SGLT2 and ACE inhibitor therapy in diabetic Dahl S rats |
| Q38607632 | Responses of renal hemodynamics and tubular functions to acute sodium-glucose cotransporter 2 inhibitor administration in non-diabetic anesthetized rats |
| Q38113101 | Review of insulin-dependent and insulin-independent agents for treating patients with type 2 diabetes mellitus and potential role for sodium-glucose co-transporter 2 inhibitors |
| Q37981884 | SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. |
| Q34470786 | SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria |
| Q37653114 | Safety, pharmacokinetics, and pharmacodynamics of single and multiple luseogliflozin dosing in healthy Japanese males: a randomized, single-blind, placebo-controlled trial. |
| Q38662950 | Sodium glucose co-transporter 2 inhibitor luseogliflozin in the management of type 2 diabetes: a drug safety evaluation. |
| Q38730067 | The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE -/- mice fed a western diet |
| Q38126109 | The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors |
| Q37219076 | Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice. |
Search more.